ReviewBiomedicines2022
Macrophage-Derived Extracellular Vesicles: A Promising Tool for Personalized Cancer Therapy.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Exercise-derived extracellular vesicles in oncology: a new frontier for translational nanomedicine.Journal of translational medicine · 2026Review
- Cisplatin-Loaded M1 Macrophage-Derived Vesicles Have Anti-Cancer Activity in Osteosarcoma.Cells · 2025Article
- Immunomodulation Through Fibroblast-Derived Extracellular Vesicles (EVs) Within 3D Polycaprolactone-Collagen Matrix.Biomimetics (Basel, Switzerland) · 2025Article
- Extracellular vesicles as biomarkers and drug delivery systems for tumor.Acta pharmaceutica Sinica. B · 2025Review
- Noninvasive in vivo imaging of macrophages: understanding tumor microenvironments and delivery of therapeutics.Biomarker research · 2025Review
- Macrophage-Derived Extracellular Vesicles: A Novel Therapeutic Alternative for Diabetic Wound.International journal of nanomedicine · 2025Review
- The dual effects of macrophage-derived extracellular vesicles on tumor cell behavior: mechanisms and clinical potential.Frontiers in oncology · 2025Review
- Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases.Pharmaceutics · 2024Review
- Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting.Drug delivery and translational research · 2023Article
- Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials.Molecules (Basel, Switzerland) · 2023Review
- Diabetic macrophage small extracellular vesicles-associated miR-503/IGF1R axis regulates endothelial cell function and affects wound healing.Frontiers in immunology · 2023Article
- Regulation of Extracellular Vesicle-Mediated Immune Responses against Antigen-Specific Presentation.Vaccines · 2022Review
- Extracellular vesicles derived from macrophages: Current applications and prospects in tumors.Frontiers in bioengineering and biotechnology · 2022Review
- Emerging innovations on exosome-based onco-therapeutics.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of cancer is increasing dramatically, affecting all ages of the population and reaching an ever higher worldwide mortality rate. The lack of therapies' efficacy is due to several factors such as a delay in diagnosis, tumor regrowth after surgical resection and the occurrence of multidrug resistance (MDR). Tumor-associated immune cells and the tumor microenvironment (TME) deeply affect the tumor's progression, leading to several physicochemical changes compared to physiological conditions. In this scenario, macrophages play a crucial role, participating both in tumor suppression or progression based on the polarization of onco-suppressive M1 or pro-oncogenic M2 phenotypes. Moreover, much evidence supports the pivotal role of macrophage-derived extracellular vesicles (EVs) as mediators in TME, because of their ability to shuttle the cell-cell and organ-cell communications, by delivering nucleic acids and proteins. EVs are lipid-based nanosystems with a broad size range distribution, which reflect a similar composition of native parent cells, thus providing a natural selectivity towards target sites. In this review, we discuss the impact of macrophage-derived EVs in the cancer's fate as well as their potential implications for the development of personalized anticancer nanomedicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.